Design Therapeutics Inc. (NASDAQ:DSGN) saw an upside of 1.95% to close Tuesday at $2.09 after adding $0.04 on the day. The 5-day average trading volume is 2,454,060 shares of the company’s common stock. It has gained $2.34 in the past week and touched a new high 1 time within the past 5 days. An average of 1,526,105 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 780,904.
DSGN’s 1-month performance is -70.77% or -$5.27 on its low of $1.94 reached on 08/22/23. The company’s shares have touched a 52-week low of $1.99 and high of $25.03, with the stock’s rally to the 52-week high happening on 01/03/23. YTD, DSGN has lost -79.63% or -$8.17 and has reached a new high 1 time. However, the current price is down -91.65% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
DSGN stock has a beta of 1.77. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 0.39.
Design Therapeutics Inc.’s quick ratio for the period ended June 29 was 25.20, with the current ratio over the same period at 25.20.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income grew 24.77% to -$19.94 million, while revenue of -$19.29 million was 3.26% off the previous quarter. Analysts expected DSGN to announce -$0.4 per share in earnings in its latest quarter, but it posted -$0.36, representing a 10.00% surprise. DSGN stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 14.84 million, with total debt at $3.38 million. Shareholders hold equity totaling $55.99 million.
Let’s look briefly at Design Therapeutics Inc. (DSGN) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 22 August was 12.32% to suggest the stock is trending oversold, with historical volatility in this time period at 596.80%.
The stock’s 5-day moving average is $2.10, reflecting a -3.46% or -$0.08 change from its current price. DSGN is currently trading -71.25% above its 20-day SMA, -63.97% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -60.93% and SMA200 by-86.52%.
Stochastic %K and %D was 1.64% and 1.29% and the average true range (ATR) pointed at 0.59. The RSI (14) points at 17.90%, while the 14-day stochastic is at 2.48% with the period’s ATR at 0.57. The stock’s 9-day MACD Oscillator is pointing at -1.83 and -3.09 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Design Therapeutics Inc. (NASDAQ: DSGN), Wedbush downgraded it to a Neutral rating. They previously had an Outperform rating on the stock. Analysts offering their rating for DSGN stock have a consensus rating for the stock as Hold. Currently, 0 brokerage advisors rate DSGN as a “sell,”, while 3 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 1 have offered a “buy” rating.
What is DSGN’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $6.00 and a high of $42.00, with their median price target at $6.50. Looking at these predictions, the average price target given by analysts is for Design Therapeutics Inc. (DSGN) stock is $15.25.
